Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Feb;70(2):787–793. doi: 10.1128/jvi.70.2.787-793.1996

Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates.

A M Bonneau 1, P Kibler 1, P White 1, C Bousquet 1, N Dansereau 1, M G Cordingley 1
PMCID: PMC189880  PMID: 8551616

Abstract

Herpes simplex virus (HSV) encodes its own ribonucleotide reductase (RR), which provides the high levels of deoxynucleoside triphosphates required for viral DNA replication in infected cells. HSV RR is composed of two distinct subunits, R1 and R2, whose association is required for enzymatic activity. Peptidomimetic inhibitors that mimic the C-terminal amino acids of R2 inhibit HSV RR by preventing the association of R1 and R2. These compounds are candidate antiviral therapeutic agents. Here we describe the in vitro selection of HSV type 1 KOS variants with three- to ninefold-decreased sensitivity to the RR inhibitor BILD 733. The resistant isolates have growth properties in vitro similar to those of wild-type KOS but are more sensitive to acyclovir, possibly as a consequence of functional impairment of their RRs. A single amino acid substitution in R1 (Ala-1091 to Ser) was associated with threefold resistance to BILD 733, whereas an additional substitution (Pro-1090 to Leu) was required for higher levels of resistance. These mutations were reintroduced into HSV type 1 KOS and shown to be sufficient to confer the resistance phenotype. Studies in vitro with RRs isolated from cells infected with these mutant viruses demonstrated that these RRs bind BILD 733 more weakly than the wild-type enzyme and are also functionally impaired, exhibiting an elevated dissociation constant (Kd) for R1-R2 subunit association and/or reduced activity (kcat). This work provides evidence that the C-terminal end of HSV R1 (residues 1090 and 1091) is involved in R2 binding interactions and demonstrates that resistance to subunit association inhibitors may be associated with compromised activity of the target enzyme.

Full Text

The Full Text of this article is available as a PDF (255.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Averett D. R., Lubbers C., Elion G. B., Spector T. Ribonucleotide reductase induced by herpes simplex type 1 virus. Characterization of a distinct enzyme. J Biol Chem. 1983 Aug 25;258(16):9831–9838. [PubMed] [Google Scholar]
  2. Brandt C. R., Kintner R. L., Pumfery A. M., Visalli R. J., Grau D. R. The herpes simplex virus ribonucleotide reductase is required for ocular virulence. J Gen Virol. 1991 Sep;72(Pt 9):2043–2049. doi: 10.1099/0022-1317-72-9-2043. [DOI] [PubMed] [Google Scholar]
  3. Brazeau P., Ling N., Böhlen P., Esch F., Ying S. Y., Guillemin R. Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7909–7913. doi: 10.1073/pnas.79.24.7909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cameron J. M., McDougall I., Marsden H. S., Preston V. G., Ryan D. M., Subak-Sharpe J. H. Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol. 1988 Oct;69(Pt 10):2607–2612. doi: 10.1099/0022-1317-69-10-2607. [DOI] [PubMed] [Google Scholar]
  5. Chatis P. A., Crumpacker C. S. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother. 1992 Aug;36(8):1589–1595. doi: 10.1128/aac.36.8.1589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Coen D. M., Goldstein D. J., Weller S. K. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob Agents Chemother. 1989 Aug;33(8):1395–1399. doi: 10.1128/aac.33.8.1395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Coen D. M. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Res. 1991 May;15(4):287–300. doi: 10.1016/0166-3542(91)90010-o. [DOI] [PubMed] [Google Scholar]
  8. Cohen E. A., Charron J., Perret J., Langelier Y. Herpes simplex virus ribonucleotide reductase induced in infected BHK-21/C13 cells: biochemical evidence for the existence of two non-identical subunits, H1 and H2. J Gen Virol. 1985 Apr;66(Pt 4):733–745. doi: 10.1099/0022-1317-66-4-733. [DOI] [PubMed] [Google Scholar]
  9. Cohen E. A., Gaudreau P., Brazeau P., Langelier Y. Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2. Nature. 1986 May 22;321(6068):441–443. doi: 10.1038/321441a0. [DOI] [PubMed] [Google Scholar]
  10. Conner J., Furlong J., Murray J., Meighan M., Cross A., Marsden H., Clements J. B. Herpes simplex virus type 1 ribonucleotide reductase large subunit: regions of the protein essential for subunit interaction and dimerization. Biochemistry. 1993 Dec 14;32(49):13673–13680. doi: 10.1021/bi00212a036. [DOI] [PubMed] [Google Scholar]
  11. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986 May 22;89(2):271–277. doi: 10.1016/0022-1759(86)90368-6. [DOI] [PubMed] [Google Scholar]
  12. Dutia B. M., Frame M. C., Subak-Sharpe J. H., Clark W. N., Marsden H. S. Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides. Nature. 1986 May 22;321(6068):439–441. doi: 10.1038/321439a0. [DOI] [PubMed] [Google Scholar]
  13. Filatov D., Ingemarson R., Gräslund A., Thelander L. The role of herpes simplex virus ribonucleotide reductase small subunit carboxyl terminus in subunit interaction and formation of iron-tyrosyl center structure. J Biol Chem. 1992 Aug 5;267(22):15816–15822. [PubMed] [Google Scholar]
  14. Goldstein D. J., Weller S. K. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology. 1988 Sep;166(1):41–51. doi: 10.1016/0042-6822(88)90144-4. [DOI] [PubMed] [Google Scholar]
  15. Graham F. L., van der Eb A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973 Apr;52(2):456–467. doi: 10.1016/0042-6822(73)90341-3. [DOI] [PubMed] [Google Scholar]
  16. Idowu A. D., Fraser-Smith E. B., Poffenberger K. L., Herman R. C. Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo. Antiviral Res. 1992 Feb;17(2):145–156. doi: 10.1016/0166-3542(92)90048-a. [DOI] [PubMed] [Google Scholar]
  17. Jacobson J. G., Leib D. A., Goldstein D. J., Bogard C. L., Schaffer P. A., Weller S. K., Coen D. M. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology. 1989 Nov;173(1):276–283. doi: 10.1016/0042-6822(89)90244-4. [DOI] [PubMed] [Google Scholar]
  18. Kibler P. K., Duncan J., Keith B. D., Hupel T., Smiley J. R. Regulation of herpes simplex virus true late gene expression: sequences downstream from the US11 TATA box inhibit expression from an unreplicated template. J Virol. 1991 Dec;65(12):6749–6760. doi: 10.1128/jvi.65.12.6749-6760.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Krogsrud R. L., Welchner E., Scouten E., Liuzzi M. A solid-phase assay for the binding of peptidic subunit association inhibitors to the herpes simplex virus ribonucleotide reductase large subunit. Anal Biochem. 1993 Sep;213(2):386–394. doi: 10.1006/abio.1993.1436. [DOI] [PubMed] [Google Scholar]
  20. Langlois M., Allard J. P., Nugier F., Aymard M. A rapid and automated colorimetric assay for evaluating the sensitivity of herpes simplex strains to antiviral drugs. J Biol Stand. 1986 Jul;14(3):201–211. doi: 10.1016/0092-1157(86)90004-1. [DOI] [PubMed] [Google Scholar]
  21. Liuzzi M., Déziel R., Moss N., Beaulieu P., Bonneau A. M., Bousquet C., Chafouleas J. G., Garneau M., Jaramillo J., Krogsrud R. L. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature. 1994 Dec 15;372(6507):695–698. doi: 10.1038/372695a0. [DOI] [PubMed] [Google Scholar]
  22. Liuzzi M., Scouten E., Ingemarson R. Inhibition of herpes simplex virus ribonucleotide reductase by synthetic nonapeptides: a potential antiviral therapy. Adv Exp Med Biol. 1992;312:129–138. doi: 10.1007/978-1-4615-3462-4_13. [DOI] [PubMed] [Google Scholar]
  23. Mann G. J., Gräslund A., Ochiai E., Ingemarson R., Thelander L. Purification and characterization of recombinant mouse and herpes simplex virus ribonucleotide reductase R2 subunit. Biochemistry. 1991 Feb 19;30(7):1939–1947. doi: 10.1021/bi00221a030. [DOI] [PubMed] [Google Scholar]
  24. McClements W., Yamanaka G., Garsky V., Perry H., Bacchetti S., Colonno R., Stein R. B. Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation. Virology. 1988 Jan;162(1):270–273. doi: 10.1016/0042-6822(88)90421-7. [DOI] [PubMed] [Google Scholar]
  25. McGeoch D. J., Dalrymple M. A., Davison A. J., Dolan A., Frame M. C., McNab D., Perry L. J., Scott J. E., Taylor P. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol. 1988 Jul;69(Pt 7):1531–1574. doi: 10.1099/0022-1317-69-7-1531. [DOI] [PubMed] [Google Scholar]
  26. Moss N., Beaulieu P., Duceppe J. S., Ferland J. M., Gauthier J., Ghiro E., Goulet S., Grenier L., Llinas-Brunet M., Plante R. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents. J Med Chem. 1995 Sep 1;38(18):3617–3623. doi: 10.1021/jm00018a022. [DOI] [PubMed] [Google Scholar]
  27. Moss N., Déziel R., Adams J., Aubry N., Bailey M., Baillet M., Beaulieu P., DiMaio J., Duceppe J. S., Ferland J. M. Inhibition of herpes simplex virus type 1 ribonucleotide reductase by substituted tetrapeptide derivatives. J Med Chem. 1993 Oct 1;36(20):3005–3009. doi: 10.1021/jm00072a021. [DOI] [PubMed] [Google Scholar]
  28. Paradis H., Gaudreau P., Brazeau P., Langelier Y. Mechanism of inhibition of herpes simplex virus (HSV) ribonucleotide reductase by a nonapeptide corresponding to the carboxyl terminus of its subunit 2. Specific binding of a photoaffinity analog, [4'- azido-Phe6] HSV H2-6(6-15), to subunit 1. J Biol Chem. 1988 Nov 5;263(31):16045–16050. [PubMed] [Google Scholar]
  29. Uhlin U., Eklund H. Structure of ribonucleotide reductase protein R1. Nature. 1994 Aug 18;370(6490):533–539. doi: 10.1038/370533a0. [DOI] [PubMed] [Google Scholar]
  30. Yamada Y., Kimura H., Morishima T., Daikoku T., Maeno K., Nishiyama Y. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis. 1991 Dec;164(6):1091–1097. doi: 10.1093/infdis/164.6.1091. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES